Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 30;35(Suppl 1):27-36.
doi: 10.31138/mjr.311023.sji. eCollection 2024 Mar.

Selective JAK-Inhibitors in Spondyloarthritis

Konstantinos D Vassilakis  1 , Konstantina Magiouf  1 , Stefan Siebert  2 , George E Fragoulis  1   2
Affiliations
Review

Selective JAK-Inhibitors in Spondyloarthritis

Konstantinos D Vassilakis et al. Mediterr J Rheumatol. .

Abstract

As our research interest and knowledge increases in the field of Spondyloarthritis, new aspects also emerge as regards to their therapeutic approach. JAK inhibitors (JAKi) are a relatively new treatment option, aiming molecules in the JAK-STAT pathway, which has a leading role in the pathophysiology of both Psoriatic Arthritis and Axial Spondyloarthritis. JAKi exhibit different selectivity towards the four different members of the JAK family (namely JAK1, JAK2, JAK3, and TYK2), possibly reflecting different efficacy and safety profile. Although knowledge is more consolidated for rheumatoid arthritis in which JAKi are being used for more than 10 years, data are still accumulating for PsA/SpA. In this review we aim to present and assess current knowledge about the efficacy of JAKi (with a focus on selective JAKi) in the treatment of patients with SpA and evaluate their safety profile as some concerns may arise around this therapeutic option.

Keywords: JAK-inhibitors; PsA; axSpA; efficacy; safety; spondylarthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Fragoulis GE, Pappa M, Evangelatos G, Iliopoulos A, Sfikakis PP, Tektonidou MG. Axial psoriatic arthritis and ankylosing spondylitis: same or different? A real-world study with emphasis on comorbidities. Clin Exp Rheumatol 2022. Jul;40(7):1267–72. - PubMed
    1. Fragoulis GE, Evangelatos G, Tentolouris N, Fragkiadaki K, Panopoulos S, Konstantonis G, et al. Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. Ther Adv Musculoskelet Dis 2020;12. - PMC - PubMed
    1. Gialouri CG, Evangelatos G, Zhao SS, Kouna K, Karamanakos A, Iliopoulos A, et al. Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients’ perception? Mood disorders in psoriatic arthritis. Clin Exp Rheumatol 2023. Jan;41(1):159–65. - PubMed
    1. Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology (Oxford) 2020. Oct 1;59(Suppl4):iv79–89. - PMC - PubMed
    1. Gialouri CG, Evangelatos G, Fragoulis GE. Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors? Mediterr J Rheumatol 2022. Mar;33(Suppl 1):150–61. - PMC - PubMed

LinkOut - more resources